NCT04843904View on ClinicalTrials.gov

Safe Accelerated Venetoclax Escalation in CLL

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

June 2, 2025

Study Completion Date

June 2, 2030

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Venetoclax

Tablet, taken by mouth

DRUG

Obinutuzumab

Given as an infusion into the vein (intravenous, IV).

DRUG

Rituximab

Given as an infusion into the vein (intravenous, IV).

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER